ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Fellow Health Study Demonstrates 82% Compliance Rates with Mail-In Postvasectomy Semen Analysis

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the findings of a study demonstrating the effectiveness of its mail-in postvasectomy semen analysis (PVSA) kits. The research, published in the Journal of Urology, found that Fellow Health’s mail-in testing significantly improves compliance rates, addressing longstanding challenges in verifying vasectomy success.

Each year, about half a million vasectomies are performed in the U.S. While the American Urological Association (AUA) recommends PVSA to confirm procedural success before relying on vasectomy as contraception, compliance has historically been low due to barriers like distance to testing facilities, time constraints, and lack of transportation. Most practices achieve 30-50% compliance even with mail-in testing, while a few small centers have reported up to 70% compliance through labor-intensive follow-ups.

The two-year prospective cohort study analyzed data from over 16,000 men across the U.S. who received Fellow Health’s PVSA mail-in kits. Compliance was measured by the return of samples to Fellow’s CLIA-certified laboratory within defined observation periods. Results showed an initial compliance rate of 69% at 18 weeks, increasing to 82% by 40 weeks.

“Traditional compliance efforts rely on clinics to shoulder the burden with time-consuming follow-ups or use basic mail-in options that fail to fully solve the problem,” said James F. Smith, MD, MS, Chief Medical Officer and NYS Laboratory Director of Fellow Health. “Fellow Health’s comprehensive system tackles these barriers through excellent customer support, automated reminders, and a streamlined supply chain, driving compliance rates far beyond what clinics or other mail-in systems have been able to achieve.”

“PVSA compliance has been a frustrating challenge for both patients and clinics,” said Brian Hogan, CEO of Fellow Health. “This study underscores our commitment to removing barriers to PVSA compliance and improving reproductive health outcomes across the U.S. Fellow Health is setting a new standard for mail-in PVSA testing with the highest published compliance rates to date.”

About Fellow Health

Founded in 2018, Fellow Health is a pioneering company dedicated to advancing male reproductive health through innovative and comprehensive mail-in testing solutions. The company partners with more than 1,500 top clinical practices, processing over 300 patient samples daily through their CLIA-certified lab, and is the only mail-in fertility test with peer-reviewed validation data. Fellow Health has secured funding from leading life sciences and technology investors, including 5AM Ventures, Genoa Ventures, Human Capital, and Mantis Venture Capital.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.